

Pharmacy and Therapeutics Committee Approvals, April 2007

P&T Date: April 24, 2007

AGENDA ITEM	P&T COMMITTEE DECISION	COMMENTS
<ul style="list-style-type: none"> • DECITABINE (DACOGEN[®]) 	<p style="text-align: center;">NOT ADDED TO FORMULARY.</p> <p style="text-align: center;">AZACITIDINE (VIDAZA[®]) REMOVED FROM FORMULARY</p> <p style="text-align: center;">BOTH AGENTS AVAILABLE ON A CASE-BY-CASE BASIS</p>	<ul style="list-style-type: none"> • Indication: Treatment of patients with myelodysplastic syndromes (MDS) • Mechanism of Action: An antimetabolite, pyrimidine analogue that induces DNA hypomethylation by inhibiting methyltransferase. This in turn leads to either cellular differentiation or apoptosis. • Adverse effects: Most commonly: neutropenia, thrombocytopenia, anemia, pyrexia, nausea, cough, petechiae, constipation, diarrhea, hyperglycemia, and febrile neutropenia • Precautions: Myelosuppression, hepatic and renal impairment (not studied in patients with hepatic and renal dysfunction).
<ul style="list-style-type: none"> • Rh_o(D) IMMUNE GLOBULIN INTRAVENOUS (WINRHO[®]) 	<p>ADDED TO FORMULARY.</p>	<ul style="list-style-type: none"> • Indication: Treatment of ITP in non-splenectomized Rh_o(D) positive children with chronic or acute ITP and adults with chronic ITP. WinRho SDF is not indicated for non-ITP causes of thrombocytopenia, in splenectomized patients, or in patients who are Rh_o(D) negative. • Mechanism of Action: Although the mechanism of action is not completely understood, it is thought to be due to the formation of anti-Rh_o(D)-coated RBC complexes resulting in Fc receptor blockade. • Adverse effects: Most commonly: headache, chills, fevers, asthenia, diarrhea, nausea/vomiting, arthralgia, dizziness, hypotension, hypertension, somnolence, vasodilation, pruritis, rash, and sweating.
<ul style="list-style-type: none"> • SITAGLIPTIN PHOSPHATE (JANUVIA[®]) 	<p>ADDED TO FORMULARY.</p>	<ul style="list-style-type: none"> • Indication: Mono- or combination therapy (with metformin or thiazolidinediones) to improve glycemic control in type 2 diabetes • Mechanism of Action: Inhibition of dipeptidyl peptidase-4 (DPP-4) to increase concentrations and prolong action of incretins involved in glucose homeostasis • Adverse effects: Most commonly: upper respiratory tract infection, nasopharyngitis and headache • Precautions: Not to be used to treat DKA or type 1 diabetes • Dosage and Administration: 100mg once daily with or without food; dose must be adjusted for renal impairment
<ul style="list-style-type: none"> • POLY-VITAMINS + IRON 	<p>ADDED TO FORMULARY.</p>	<ul style="list-style-type: none"> • For pediatric patients
<ul style="list-style-type: none"> • FDA MANDATE TO DISCONTINUE MARKETING 	<p>REMOVED FROM FORMULARY.</p>	<ul style="list-style-type: none"> • Trimethobenzamide Suppositories (Tigan[®]) • Pergolide (Permax[®]) • Tegaserod (Zelnorm[®])
<ul style="list-style-type: none"> • AUTOMATIC SUBSTITUTIONS 	<ul style="list-style-type: none"> • Lansoprazole (Prevacid[®]) IVPB or PO/enteral tube 30mg TO esomeprazole (Nexium[®]) IV push or PO/enteral tube 40mg • Lansoprazole (Prevacid[®]) 60mg IVPB bolus followed by 6mg/hr continuous infusion TO esomeprazole (Nexium[®]) 80mg IVPB bolus followed by 8mg/hr continuous infusion • Ultracet[®] TO acetaminophen 325mg + tramadol 50mg tablets at the same frequency • Erythromycin 250mg IV every 6 hrs TO 500mg IV every 6 hrs for premature rupture of membranes (PROM) 	

- **Glucophage**

Glucophage XR [®] Ordered	Glucophage [®] substitution
500 mg daily	500 mg daily w/ breakfast
750 mg daily	850 mg daily w/ breakfast
≥ 1000 mg daily	Same total daily dose, divided BID (B/D)
- **Penicillin G 2.5 million units IV** every 4 hours **TO 3 million units IV** every 4 hours for Group B streptococcal prophylaxis
- **Erythromycin 250mg IV** every 6 hours **TO 500mg** for premature rupture of membranes (PROM)

• **ACINETOBACTER
TREATMENT GUIDELINE
REVISION**



Requests for full monographs or questions regarding this listing may be addressed to the Drug Information Center at **(310) 423-3784**

Russell Christensen, PharmD
 Angela Hirai Yang, PharmD
 Hai Tran, Pharm.D.
 Rita Shane, Pharm.D., FASHP

Clinical Pharmacist
Pharmacy Program Coordinator
Clinical Coordinator
Director, Department of Pharmacy